UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number: 001-42410
BrilliA Inc
220 Orchard Road
Unit 05-01, Midpoint Orchard
Singapore 238852
Tel: +65 6235 3388
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form
40-F ☐
On November 29, 2024, BrilliA Inc (the “Company”)
closed the initial public offering (the “IPO”) of its 2,500,000 Class A ordinary shares, par value US$0.00005 per share (the
“Shares”). The Company completed the IPO pursuant to its registration statement on Form F-1 (File No. 333-282056), initially
filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 12, 2024 (as amended, the “Registration
Statement”). The Registration Statement was declared effective by the SEC on November 19, 2024. The
Shares were priced at $4.00 per share, and the IPO was conducted on a firm commitment basis. The Company’s Class
A ordinary shares commenced trading on The NYSE American under the ticker symbol “BRIA” on November 27, 2024.
In connection with the IPO, the Company entered
into an underwriting agreement, dated November 26, 2024 (the “Underwriting Agreement”), with A.G.P./Alliance Global Partners
(“Underwriter”), the sole underwriter.
The net proceeds to
the Company from the IPO, after deducting the underwriting discount, the Underwriters’ fees and expenses, and the Company’s
estimated offering expenses, were approximately $7.5 million.
The Underwriting Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”),
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
“lock-up” agreements, the Company and each director, executive officer, and owner of at least 5% of the Company’s outstanding
Class A ordinary shares (or securities convertible or exercisable into Class A ordinary shares) of the Company have agreed, subject to
customary exceptions, not to sell, transfer or otherwise dispose of securities of the Company, without the prior written consent of the
Underwriters, for a period of 180 days after the effective date of the Registration Statement.
The foregoing description
of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement,
which is furnished as Exhibit 1.1 to this Current Report on Form 6-K and is incorporated herein by reference. A form of the lock-up agreement is furnished as Exhibit 10.1 to this Current Report on Form 6-K and is incorporated herein by reference.
On November 26, 2024,
the Company issued a press release announcing the pricing of the IPO. On November 29, 2024, the Company issued a press release announcing
the closing of the IPO. Copies of these press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated
herein by reference.
On November 29, 2024, the Company also issued to the Representative warrants to purchase up to 125,000 Class A Ordinary Shares (the “Representative’s
Warrant”), a copy of which is attached as Exhibit 4.1 to this Current Report on Form 6-K and is incorporated herein by reference.
The information
contained in this Current Report on Form 6-K, the Underwriting Agreement furnished as Exhibit 1.1, 4.1, 10.1, and the press releases
furnished as Exhibits 99.1 and 99.2 shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the
Company’s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall
be expressly set forth by specific reference in any such filing.
EXHIBIT INDEX
The following exhibits are furnished as part of this Current Report
on Form 6-K:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
BrilliA Inc |
| |
|
|
| Date: November 29, 2024 |
By: |
/s/ Kendrew Hartanto |
| |
Name: |
Kendrew Hartanto |
| |
Title: |
Chief Executive Officer |
Exhibit 1.1
BRILLIA INC
UNDERWRITING AGREEMENT
November 26, 2024
A.G.P./Alliance Global Partners
As Representative of the several Underwriters named on Schedule 1 attached hereto
590 Madison Avenue, 28th Floor
New York, NY 10022
Ladies and Gentlemen:
The undersigned, BrilliA Inc,
a corporation formed under the laws of Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”)
with A.G.P./Alliance Global Partners (hereinafter referred to as “you” (including its correlatives) or the “Representative”)
and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative
and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”)
as follows:
1. Purchase
and Sale of Securities.
1.1 Firm Shares.
1.1.1 Nature and
Purchase of Shares.
(i) On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of 2,500,000 shares (the “Firm Shares”) of the Company’s
Class A ordinary shares, par value $0.00005 per share (the “Class A Shares”).
(ii) The
Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective
names on Schedule 1 attached hereto and made a part hereof. The purchase price for one Firm Share shall be $3.72 (net of underwriting
discounts). The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus
(as defined in Section 2.1.1 hereof).
1.1.2 Firm Shares
Payment and Delivery.
(i) Delivery
and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the first (1st) Business Day following the effective date
(the “Effective Date”) of the Registration Statement (as defined in Section 2.1.1 below) under the Securities Act of
1933, as amended (the “Securities Act”) (or the second (2nd) Business Day following the Effective Date if the pricing
for the Offering (as defined in Section 1.2.1 below) occurs after 4:01 p.m., Eastern time on the Effective Date) or at such earlier
time as shall be agreed upon by the Representative and the Company, at the offices of Lewis Brisbois Bisgaard & Smith LLP, 45 Fremont
Street, 30th Floor, San Francisco, California 94105 (“Representative Counsel”), or at such other place (or
remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date
of delivery and payment for the Firm Shares is called the “Closing Date.”
(ii) Payment
for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company
upon delivery of the Firm Shares via the Depository Trust Company (“DTC”). The Firm Shares shall be registered in such
name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business Days prior
to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment by the Representative
for all of the Firm Shares. The term “Business Day” means any day other than a Saturday, a Sunday or a legal holiday
or a day on which banking institutions are authorized or obligated by law to close in New York, New York.
1.2 Over-allotment
Option.
1.2.1 Option Shares.
For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Company hereby
grants to the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 375,000 Class A
Shares from the Company, representing fifteen percent (15%) of the Firm Shares sold in the offering (the “Option Shares”).
The purchase price to be paid per Option Share shall be equal to the price per Firm Share set forth in Section 1.1.1 hereof. The Firm
Shares and the Option Shares are hereinafter referred to together as the “Shares.” The offering and sale of the Shares
is hereinafter referred to as the “Offering.”
1.2.2 Exercise of
Option. The Over-Allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Underwriters as to all (at
any time) or any part (from time to time) of the Option Shares within forty-five (45) days after the date of the Prospectus (as defined
below). The Underwriters shall not be under any obligation to purchase any Option Shares prior to the exercise of the Over-Allotment
Option. The Over-Allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative,
which must be confirmed in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option
Shares to be purchased and the date and time for delivery of and payment for the Option Shares (the “Option Closing Date”),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by
the Company and the Representative, at the offices of Representative Counsel, or at such other place (including remotely by facsimile
or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the
Option Shares does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-Allotment
Option with respect to all or any portion of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company
shall become obligated to sell to the Underwriters the number of Option Shares specified in such notice and (ii) each of the Underwriters,
acting severally and not jointly, shall purchase that portion of the total number of Option Shares then being purchased as set forth
in Schedule 1 opposite the name of such Underwriter.
1.2.3 Payment and
Delivery. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds,
payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing
the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Shares shall be registered in such
name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business Days
prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment
by the Underwriters for applicable Option Shares.
1.3 Representative’s
Warrants.
1.3.1 Purchase Warrants.
The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date, and each Option Closing Date, a
warrant to purchase such number of Class A Shares equal to 5.0% of the number of Shares purchased on such Closing Date or Option Closing
Date, as the case may be. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s
Warrant Agreement”), shall be exercisable, in whole or in part, commencing 180 days after the Effective Date and expiring on
the five year anniversary of the Effective Date at an initial exercise price per Common Share of $5.20, which is equal to 130.0% of the
public offering price of each Share. The Representative’s Warrant Agreement and the Class A Shares issuable upon exercise thereof
(the “Representative’s Shares”) are sometimes hereinafter referred to together as the “Representative’s
Securities.”
1.3.2 Delivery.
Delivery of the Representative’s Warrant Agreement shall be made on the Closing Date and shall be issued in the name or names and
in such authorized denominations as the Representative may reasonably request.
2. Representations
and Warranties of the Company. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined
below), as of the Closing Date and as of the Option Closing Date, as follows:
2.1 Filing of
Registration Statement.
2.1.1 Pursuant to
the Securities Act. The Company has filed with the U.S. Securities and Exchange Commission (the “Commission”)
an initial registration statement, and an amendment or amendments thereto, on Form F-1 (File No. 333-282056), including any related prospectus
or prospectuses, for the registration of the sale of Shares under the Securities Act, which registration statement and amendment or amendments
have been prepared by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and
regulations of the Commission promulgated thereunder (the “Securities Act Regulations”) and contains and will contain
all material statements that are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations.
Except as the context may otherwise require, such registration statement, as amended, on file with the Commission at the time the registration
statement became effective (including the Preliminary Prospectus included in the registration statement, financial statements, schedules,
exhibits and all other documents filed as a part thereof and all information deemed to be a part thereof as of the Effective Date pursuant
to paragraph (b) of Rule 430A of the Securities Act Regulations (the “Rule 430A Information”)), is referred to herein
as the “Registration Statement.” If the Company files any registration statement pursuant to Rule 462(b) of the
Securities Act Regulations, then after such filing, the term “Registration Statement” shall include such registration statement
filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission on the date hereof.
Each prospectus used prior
to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such
effectiveness and prior to the execution and delivery of this Agreement, is herein called a “Preliminary Prospectus.”
The Preliminary Prospectus, subject to completion, dated October 15, 2024, which was included in the Registration Statement immediately
prior to the Applicable Time is hereinafter called the “Pricing Prospectus.” The final prospectus in the form first
furnished to the Underwriters for use in the Offering is hereinafter called the “Prospectus.” Any reference to the
“most recent Preliminary Prospectus” shall be deemed to refer to the latest Preliminary Prospectus included in the
Registration Statement.
“Applicable Time”
means 5:00 p.m., Eastern Time, on the date of this Agreement.
“Issuer Free
Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Securities Act Regulations
(“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the
Securities Act Regulations) relating to the Shares that is (i) required to be filed with the Commission by the Company, (ii) a “road
show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission,
or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or
of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or,
if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).
“Issuer General
Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective
investors (other than a “bona fide electronic road show,” as defined in Rule 433), as evidenced by its being specified
in Schedule 2-B hereto.
“Issuer Limited
Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Pricing Disclosure
Package” means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus
and the information included on Schedule 2-A hereto, all considered together.
2.1.2 Pursuant to
the Exchange Act. The Class A Shares are registered pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). The Company has taken no action designed to, or likely to have the effect of, terminating the
registration of the Class A Shares under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration.
2.2 Intentionally
omitted.
2.3 No Stop Orders,
etc. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued any order preventing
or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company’s
knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any)
from the Commission for additional information.
2.4 Exchange Listing.
The Class A Shares have been approved for listing on the NYSE American LLC (the “Exchange”), subject only to the official
notice of issuance and evidence of satisfactory distribution. The Company is in compliance with all applicable listing requirements of
the Exchange, subject to the completion of the Offering.
2.5 Disclosures
in Registration Statement.
2.5.1 Compliance
with Securities Act and 10b-5 Representation.
(i) Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects
with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus,
at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the
Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the
Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.
(ii) Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any
Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
(iii) The
Pricing Disclosure Package, as of the Applicable Time, at the Closing Date, or at any Option Closing Date (if any), did not, does not
and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus
hereto does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus
or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus
as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided however, that this
representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing
Prospectus, the Pricing Disclosure Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and
agree that such information provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the “Underwriting”
section of the Prospectus: (a) the information set forth under the sub-captions “Price Stabilization, Short Positions and Penalty
Bids,” and “Electronic Distribution” and (b) the table showing the number of securities to be purchased by each
Underwriter (the “Underwriters’ Information”).
(iv) Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing
with the Commission pursuant to Rule 424(b), at the Closing Date, or at any Option Closing Date (if any), included, includes or will include
an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and
warranty shall not apply to the Underwriters’ Information.
2.5.2 Disclosure
of Agreements. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
conform in all material respects to the descriptions thereof contained therein, and there are no agreements or other documents required
by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed.
Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound
or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii) is
material to the Company’s business, has been duly authorized and validly executed by the Company, is in full force and effect in
all material respects and is enforceable against the Company and, to the Company’s knowledge, the other parties thereto, in accordance
with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors’ rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the
federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None
of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company’s knowledge, any
other party is in default thereunder and, to the Company’s knowledge, no event has occurred that, with the lapse of time or the
giving of notice, or both, would constitute a default thereunder except for a default or event which would not reasonably be expected
to result in a Material Adverse Effect (as such term is defined in Section 2.5.3 below). To the best of the Company’s knowledge,
performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing
applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction
over the Company or any of its assets or businesses (each, a “Governmental Entity”), including, without limitation,
those relating to environmental laws and regulations.
2.5.3 Organization
and Qualification. The Company is an entity duly incorporated or otherwise organized, validly existing, and, if applicable under
the laws of the jurisdiction in which they are formed, in good standing under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.
The Company has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory
officials and bodies that it needs as of the date hereof to conduct its business purpose in all material respects as described in the
Registration Statement and to own or lease its properties. The Company is not in violation nor default of any of the provisions of its
certificate or articles of incorporation, bylaws or other organizational or charter documents. The Company is duly qualified to conduct
business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case
may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability
of this Agreement, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial
or otherwise) of the Company, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a “Material Adverse Effect”)
and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification. The Company has no subsidiaries, aside from the following: PT Mirae Asia Pasifik, Bra Pro
Limited, and Brillia Holdings (Singapore) Pte. Ltd..
2.5.4 Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Representative’s Warrant Agreement and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and the Representative’s Warrant Agreement, and the consummation by each of the transactions
contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is
required by the Company, the Board of Directors or the Company’s shareholders in connection herewith or therewith other than in
connection with the Required Approvals. This Agreement and the Representative’s Warrant Agreement, upon delivery will have been
duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
2.5.5 No Conflicts.
The execution, delivery and performance by the Company of this Agreement and the Representative’s Warrant Agreement, and the issuance
and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict
with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter
documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company, or give to others any rights of termination,
amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any
agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company
is a party or by which any property or asset of the Company is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company is subject, or by which any property or asset of the Company is bound or affected; except
in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.
2.5.6 Filings, Consents
and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make
any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of this Agreement, the Representative’s Warrant Agreement, the consummation
of the transactions contemplated hereby, the application of the proceeds from the sale of the Shares as described under “Use of
Proceeds” in the most recent Preliminary Prospectus, other than: (i) the Registration of the Shares under the Securities Act; (ii)
the listing of the Shares on the Exchange; (iii) such consents, approvals, authorizations, orders, filings, registrations or qualifications
as may be registered under the Exchange Act and applicable state or foreign securities laws and/or the bylaws and rules of the Financial
Industry Regulatory Authority (“FINRA”) in connection with the purchase and sale of the Shares by the Underwriters;
and (iv) such consents, approvals, authorizations, orders, filings, registrations or qualifications, which, if not obtained, would not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect (collectively, the “Required
Approvals”).
2.5.7 Issuance of
the Shares; Registration. The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and
the Representative’s Warrant Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company. The Company has reserved from its duly authorized capitalization the maximum number of Class A Shares issuable
pursuant to this Agreement and the Representative’s Warrant Agreement.
2.5.8 Capitalization.
The equity capitalization of the Company is as set forth in the Registration Statement and the Prospectus for the dates so identified
under the caption [“Capitalization”] (other than for subsequent issuances, if any, pursuant to employee benefit plans, or
upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Prospectus). No Person
has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by this Agreement and the Representative’s Warrant Agreement. Except as set forth in the Registration Statement and the Prospectus,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any Class A Shares, or contracts, commitments, understandings or arrangements by which the Company is or may become bound
to issue additional shares of Class A Shares. Except as described in the Registration Statement and the Prospectus, the issuance and
sale of the Shares will not obligate the Company to issue Class A Shares or other securities to any Person (other than the Underwriters)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under
any of such securities. There are no outstanding securities or instruments of the Company that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company is or may become bound to redeem a security
of the Company. The Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal, state, local and foreign securities laws where applicable, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except
for the Required Approvals, no further approval or authorization of any shareholder, the Board of Directors or others is required for
the issuance and sale of the Shares. There are no shareholders agreements, voting agreements or other similar agreements with respect
to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the
Company’s shareholders.
2.5.9 Financial
Statements. The financial statements of the Company, together with related notes as set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, comply in all material respects with the applicable requirements of the Securities
Act and present fairly in all material respects the financial position and the results of operations and cash flows of the Company, at
the indicated dates and for the indicated periods. Such financial statements and related schedules have been prepared in accordance with
International Financial Reporting Standards as adopted by the International Accounting Standards Board (“IFRS”), consistently
applied throughout the periods involved, except as disclosed therein, and all adjustments necessary for a fair presentation of results
for such periods have been made. The summary and selected financial and statistical data included in the Registration Statement, the
Pricing Disclosure Package and the Prospectus present fairly in all material respects the information shown therein and such data has
been compiled on a basis consistent with the financial statements presented therein and the books and records of the Company. All disclosures
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding “non-IFRS financial measures”
comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The Company
does not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations, not disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. There are no financial statements (historical or pro
forma) that are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not
included as required.
2.5.10 Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) that are material, individually or in the aggregate, to the Company, or has entered into any transactions not
in the ordinary course of business other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to IFRS,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution
of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing
Company stock option plans, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.
2.5.11 Litigation.
Except as set forth in the Registration Statement, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of
any of this Agreement, the Representative’s Warrant Agreement or the Shares or (ii) could, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the Registration Statement, neither the
Company, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty, which could result in a Material Adverse Effect. There
has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving
the Company or any current or former director or officer of the Company.
2.5.12 Labor Relations.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company’s employees is a member of a union that relates
to such employee’s relationship with the Company, and the Company is not a party to a collective bargaining agreement, and the
Company believes that its relationships with its employees are good. To the knowledge of the Company, no executive officer of the Company,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company to any liability with respect to any
of the foregoing matters. The Company is in compliance with all federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
2.5.13 Compliance.
The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the ownership, testing,
development, manufacture, packaging, processing, use, distribution, storage or disposal of any product manufactured or distributed by
the Company (“Applicable Laws”), except as could not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect; (ii) has not received any notice of adverse finding, warning letter, untitled letter or other correspondence
or written notice from any governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”);
(iii) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such governmental authority or third
party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, except as could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) has not received written notice that any governmental
authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and have no knowledge
that any such governmental authority is considering such action, except as could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; and (vi) has filed, obtained, maintained or submitted all material reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete
and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission).
2.5.14 Environmental
Laws. The Company (i) is in material compliance with all material federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”); (ii) has
received all permits licenses or other approvals required of them under applicable Environmental Laws for their respective businesses;
and (iii) is in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
2.5.15 Regulatory
Permits. The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or
foreign regulatory authorities necessary to conduct their respective businesses as described in the Registration Statement, Pricing Disclosure
Package and the Prospectus, except where the failure to possess such permits could not reasonably be expected to result in a Material
Adverse Effect (“Material Permits”), and the Company has not received any notice of proceedings relating to the revocation
or modification of any Material Permit.
2.5.16 Title to
Assets. The Company has good and marketable title in fee simple to all real property owned by them and good and marketable title
in all personal property owned by them that is material to the business of the Company, in each case free and clear of all Liens, except
for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to
be made of such property by the Company and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves
have been made therefor in accordance with IFRS and, the payment of which is neither delinquent nor subject to penalties. Any real property
and facilities held under lease by the Company is held by them under valid, subsisting and enforceable leases with which the Company
is in compliance in all material respects.
2.5.17 Intellectual
Property. The Company has, or has rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary
or required for use in connection with their respective businesses as described in the Registration Statement, Pricing Disclosure Package
and the Prospectus and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property
Rights”). None of, and the Company has not received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the
date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect. The Company has not received, since
the date of the latest audited financial statements included within the Registration Statement, Pricing Disclosure Package and the Prospectus,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights
of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title
to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to
use all Intellectual Property Rights that are necessary to conduct its business.
2.5.18 Insurance.
The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent
and customary in the businesses in which the Company is engaged, including, but not limited to, directors and officers insurance coverage.
The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.
2.5.19 Transactions
With Affiliates and Employees. Except as set forth in the Registration Statement, none of the officers or directors of the Company
and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements
under any stock option plan of the Company.
2.5.20 Sarbanes-Oxley;
Internal Accounting Controls. The Company is in material compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission
thereunder that are effective as of the date hereof and as of the Closing Date. The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company maintains disclosure controls
and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act;
such disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries
is made known to the Company’s principal executive officer and principal financial officer by others within those entities; and
such disclosure controls and procedures are effective. The Company’s certifying officers have evaluated the effectiveness of the
disclosure controls and procedures of the Company as of the end of the period covered by the latest audited financial statements included
in the Registration Statement, Pricing Disclosure Package and the Prospectus (such date, the “Evaluation Date”). Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the
Company.
2.5.21 Certain Fees.
Except as set forth in the Registration Statement, Pricing Disclosure Package and the Prospectus, no brokerage or finder’s fees
or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, Underwriter, investment
banker, bank or other Person with respect to the transactions contemplated by this Agreement and the Representative’s Warrant Agreement.
Other than for Persons engaged by any Underwriter, if any, the Underwriters shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection
with the transactions contemplated by this Agreement and the Representative’s Warrant Agreement.
2.5.22 Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be
or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.
2.5.23 Registration
Rights. Except as set forth in the Registration Statement, no Person has any right to cause the Company to effect the registration
under the Securities Act of any securities of the Company.
2.5.24. Exchange
Act Registration. A registration statement on Form 8-A (File No. 001-42410) in respect of the registration of the Class A Shares,
pursuant to Section 12 of the Exchange Act, was filed with the Commission on November 15, 2024, such registration statement in the form
delivered to the Underwriters was declared effective by the Commission in such form; no other document with respect to such registration
statement has theretofore been filed with the Commission (the “8-A Registration Statement”). The 8-A Registration Statement
complies in all material respects with the Exchange Act.
2.5.25 [Reserved].
2.5.26 Disclosure.
All of the disclosure furnished by or on behalf of the Company to the Underwriters regarding the Company, their respective businesses
and the transactions contemplated hereby, is true and correct in all material respects and does not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made
and when made, not misleading. The Company acknowledges and agrees that no Underwriter makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.
2.5.27 No Integrated
Offering. Assuming the accuracy of the Underwriters’ representations and warranties related thereto, neither the Company,
nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under
the Securities Act.
2.5.28 Foreign Private
Issuer. The Company is a “foreign private issuer” within the meaning of Rule 405 under the Securities Act.
2.5.29 Tax Status.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company (i) has made or filed all federal, state and local income and all foreign tax returns, reports and declarations required
by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably
adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.
2.5.30 Foreign Corrupt
Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company,
has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related
to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or
to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made
by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated
in any material respect any provision of the Foreign Corrupt Practices Act.
2.5.31 Accountants.
The Company’s independent registered public accounting firm is as set forth in the Prospectus. Such accounting firm is a registered
independent public accounting firm as required by the Securities Act and the rules and regulations promulgated thereunder.
2.5.32 Acknowledgment
Regarding Underwriters’ Purchase of Shares. The Company acknowledges and agrees that each of the Underwriters is acting
solely in the capacity of an arm’s length purchaser with respect to this Agreement and the Representative’s Warrant Agreement
and the transactions contemplated hereby. The Company further acknowledges that no Underwriter is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given
by any Underwriter or any of their respective representatives or agents in connection with this Agreement and the Representative’s
Warrant Agreement and the transactions contemplated hereby is merely incidental to the Underwriters’ purchase of the Shares. The
Company further represents to each Underwriter that the Company’s decision to enter into this Agreement and the Representative’s
Warrant Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its
representatives.
2.5.33 [Reserved].
2.5.34 Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of
the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of
the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s Underwriter in connection with
the placement of the Shares.
2.5.35 [Reserved].
2.5.36 [Reserved].
2.5.37 Statistical
Information. The statistical and market and industry-related data included in the Registration Statement, Pricing Disclosure
Package and Prospectus are based on or derived from sources which the Company believes to be reliable and accurate or represent the Company’s
good faith estimates that are made on the basis of data derived from such sources and the Company has obtained the written consent to
the use of such data from sources to the extent required.
2.5.38 Office of
Foreign Assets Control. Neither the Company nor, to the Company's knowledge, any director, officer, agent, employee or affiliate
of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(“OFAC”) and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.
2.5.39 U.S. Real
Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Underwriter’s request.
2.5.40 Bank Holding
Company Act. Neither the Company nor any of its Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the
“BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”).
Neither the Company nor any of its Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding
shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to
the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Affiliates exercises a controlling influence over
the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
2.5.41 Money Laundering.
The operations of the Company are and have been conducted at all times in compliance with applicable financial record-keeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable
rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.
2.5.42 PFIC Status.
The Company does not believe it is a Passive Foreign Investment Company (“PFIC”) within the meaning of Section 1296
of the United States Internal Revenue Code of 1986, as amended, and does not believe it is likely to become a PFIC.
2.5.43 Stamp or
Other Tax. No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are
payable by or on behalf of any Underwriter to any political subdivision or taxing authority thereof or therein in connection with the
sale and delivery by the Company of the Shares to or for the sale and delivery by Shares to the Underwriters.
2.5.44 Lock-Up Agreements.
Schedule 3 hereto contains a complete and accurate list of the Company’s officers, directors and 5% or greater shareholders (collectively,
the “Lock-Up Parties”). The Company has caused each of the Lock-Up Parties to deliver to the Representative an executed
Lock-Up Agreement, in the form attached hereto as Exhibit B (the “Lock-Up Agreement”), with the lock-up period listed
on Schedule 3, prior to the execution of this Agreement.
3. Covenants
of the Company. The Company covenants and agrees as follows:
3.1 Amendments
to Registration Statement. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the
Registration Statement, the Preliminary Prospectus, the Pricing Disclosure Package or Prospectus proposed to be filed after the date
of this Agreement and not file any such amendment or supplement to which the Representative shall reasonably object in writing.
3.2 Federal Securities
Laws.
3.2.1 Compliance.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 424(b) and Rule 430A of the Securities Act Regulations,
and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration
Statement or any amendment or supplement to any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus shall have been
filed and when any post-effective amendment to the Registration Statement shall become effective; (ii) of the receipt of any comments
from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or for additional information; (iv) of the issuance
by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of
any order preventing or suspending the use of any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or of the
suspension of the qualification of the Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings
for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration
Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the
Offering of the Shares. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner
and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary
to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission
and, in the event that it was not, it will promptly file such prospectus. The Company shall use commercially reasonable efforts to prevent
the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest
possible moment.
3.2.2 Continued
Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the rules
and regulations of the Commission promulgated under the Exchange Act (the “Exchange Act Regulations”) so as to permit
the completion of the distribution of the Shares as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. If at any time when a prospectus relating to the Shares is (or, but for the exception afforded by Rule 172
of the Securities Act Regulations (“Rule 172”), would be) required by the Securities Act to be delivered in connection
with sales of the Shares, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel
for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; (ii) amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure
Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered
to a purchaser or (iii) amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as
the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly
(A) give the Representative notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement
or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply with such requirements and,
a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or supplement
and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment
or supplement to which the Representative or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters
such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company shall give the Representative
notice of its intention to make any filing pursuant to the Exchange Act or the Exchange Act Regulations from the Applicable Time until
the later of the Closing Date and the exercise in full or expiration of the Over-Allotment Option specified in Section 1.2 hereof and
will furnish the Representative with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as
the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably
object.
3.3 Delivery to
the Underwriters of Registration Statements. The Company has delivered or made available or shall deliver or make available to
the Underwriters and counsel for the Representative, without charge, signed copies of the Registration Statement as originally filed
and each amendment thereto (including exhibits filed therewith or incorporated by reference therein) and signed copies of all consents
and certificates of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement
as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement
and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with
the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
3.4 Delivery to
the Underwriters of Prospectuses. The Company has delivered or made available or will deliver or make available to each Underwriter,
without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents
to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge,
during the period when a prospectus relating to the Shares is (or, but for the exception afforded by Rule 172, would be) required
to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may
reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
3.5 Events Requiring
Notice to the Underwriters. The Company shall use commercially reasonable efforts to cause the Registration Statement to remain
effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative promptly
and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation, or the threatening,
of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings for the suspension
of the qualification of the Shares for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding
for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement
or Prospectus; (iv) of the receipt of any comments or request for any additional information from the Commission; and (v) of the happening
of any event during the period described in this Section 3.5 that, in the judgment of the Company, makes any statement of a material
fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires the making of any changes
in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in the Pricing Disclosure Package or
the Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company
shall make every reasonable effort to obtain promptly the lifting of such order.
3.6 Exchange Act
Registration. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts to maintain
the registration of the Class A Shares under the Exchange Act. The Company shall not deregister the Class A Shares under the Exchange
Act without the prior written consent of the Underwriters, such consent not to be unreasonably withheld.
3.7 Free Writing
Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any
offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free
writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under
Rule 433. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to by the
Underwriters as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply
with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending
and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company
will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus
to eliminate or correct such conflict, untrue statement or omission.
3.8 Review of
Financial Statements. For a period of three (3) years after the date of this Agreement, the Company, at its expense, shall cause
its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial statements
for the first six month of each fiscal year (or other periods required under the Commission’s rules on financial statements) immediately
preceding the announcement of any such six months (or other periods required) financial information, provided that such a provision shall
not prevent a sale, merger or similar transaction involving the Company.
3.9 Listing.
The Company shall use commercially reasonable efforts to maintain the listing of the Class A Shares (including the Shares) on the Exchange
for at least three years from the date of this Agreement.
3.10 Intentionally
Omitted.
3.11 Reports to
the Representative.
3.11.1 Periodic
Reports, etc.. For a period of one year after the date of this Agreement, the Company shall furnish to the Representative copies
of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders of
any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company shall be
required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and
every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 6-K
prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act; and
(v) such additional documents and information with respect to the Company and the affairs of any future subsidiaries of the Company as
the Representative may from time to time reasonably request; provided the Representative shall sign, if requested by the Company, a Regulation
FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Representative Counsel in connection
with the Representative’s receipt of such information. Documents filed with the Commission pursuant to its EDGAR system shall be
deemed to have been delivered to the Representative pursuant to this Section 3.11.1.
3.11.2 Transfer
Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer
agent and registrar acceptable to the Representative (the “Transfer Agent”) and, for a period of one (1) year after
the date of this Agreement, shall furnish to the Representative at the Company’s sole cost and expense such transfer sheets of
the Company’s securities as the Representative may reasonably request, including the daily and monthly consolidated transfer sheets
of the Transfer Agent and DTC. Vstock Transfer LLC is acceptable to the Representative to act as Transfer Agent for the Class A Shares.
3.11.3 [Intentionally
Omitted].
3.12 Payment of
Expenses. The Company agrees to pay on each of the Closing Date and the Option Closing Date, if any, all expenses incident to
the performance of the obligations of the Company under this Agreement, including but not limited to (a) all filing fees and communication
expenses relating to the registration of the Shares to be sold in this Offering with the Commission; (b) all Public Filing System filing
fees associated with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Shares on the Exchange
and on such other stock exchanges as the Company and Representative together determine; (d) all fees, expenses and disbursements relating
to the registration or qualification of the Shares offered under the “blue sky” securities laws of such states and other
jurisdictions as the Representative may reasonably designate (including, without limitation, all filing and registration fees, and the
reasonable fees of “blue sky” counsel); (e) all fees, expenses and disbursements relating to the registration, qualification
or exemption of the Shares under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f)
the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue
Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers’ Agreement, Underwriters’ Questionnaire
and Power of Attorney), registration statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary
and final Prospectuses as the Representative may reasonably deem necessary; (g) the costs and expenses of its public relations firm;
(h) the costs of preparing, printing and delivering certificates representing the Shares to be offered in this offering; (i) fees and
expenses of the transfer agent for the securities; (j) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities
from the Company to the Representative; (k) the fees and expenses of the Company’s accountant; (l) the fees and expenses of the
Company’s legal counsel and other agents and representatives in an aggregate amount not to exceed $200,000 (inclusive of the Advance,
as defined below). The Company has advanced $100,000 to the Representative to cover its out-of-pocket expenses (the “Advance”).
The Advance shall be returned to the Company to the extent such out-of-pocket accountable expenses are not actually incurred in accordance
with FINRA Rule 5110(g)(4)(A). In addition, the Company shall pay to the Underwriters or their respective designees their pro rata portion
(based on the number of Offered Securities purchased) of a non-accountable expense allowance of one percent (1%) of the gross proceeds
of the Offering, including proceeds from the sale of the Over-allotment Shares, if any.
3.13 Application
of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption “Use of Proceeds” in the Registration Statement, the Pricing Disclosure Package and the
Prospectus.
3.14 Delivery
of Earnings Statements to Security Holders. The Company shall make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth (15th) full calendar month following the date of this Agreement, an earnings statement
(which need not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities
Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period
of at least twelve (12) consecutive months beginning after the date of this Agreement.
3.15 Stabilization.
The Company will not take, and will use its commercially reasonable best efforts to cause its affiliates not to take, directly or indirectly,
any action designed to or that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the
Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of the Shares.
3.16 Internal
Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
(i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with IFRS and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.
3.17 Accountants.
As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Underwriters acknowledge that TAAD LLP (the “Auditor”)
is acceptable to the Representative.
3.18 FINRA.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that Company
or any of its affiliates (within the meaning of FINRA’s Conduct Rule 5121(f)(1)) directly or indirectly controls, is controlled
by, or is under common control with, or is an associated person (within the meaning of Article I, Section 1(ee) of the By-laws of FINRA)
of, any member firm of FINRA.
3.19 No Fiduciary
Duties. The Company acknowledges and agrees that the Underwriters’ responsibility to the Company is solely contractual
in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.
3.20 Company Lock-Up
Agreements.
3.20.1 Restriction
on Sales of Shares. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Representative, it will not, for a period of six (6) months from the Closing Date (the “Lock-Up Period”), (i) offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company
or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or cause to be
filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of capital stock of the Company; or (iii) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether
any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of capital stock of the Company
or such other securities, in cash or otherwise. The restrictions contained in this Section 3.20.1 shall not apply to (i) the Class A
Shares to be sold hereunder, (ii) the issuance by the Company of Class A Shares upon the exercise of a stock option or warrant or
the conversion of a security outstanding on the date hereof, of which the Representative has been advised in writing, provided that such
securities outstanding on the date hereof have not been amended since the date of this Agreement to increase the number of such securities
or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits
or combinations) or to extend the term of such securities; (iii) the issuance by the Company of stock options or shares of capital stock
of the Company under (A) any equity compensation plan of the Company to employees, officers, consultants or directors of the Company
for services rendered to the Company or (B) any stock options issued or to be issued to certain shareholders of the Company as disclosed
in the Prospectus, provided that, prior to the issuance of any Class A Shares under this subparagraph (B) to any person not delivering
a Lock-Up Agreement pursuant to Section 2.5.44 hereof, the Company will use its reasonable best efforts to obtain the agreement
of such person to not dispose, or agree to dispose, of any of Class A Shares for a period of two years from issuance; (iv) the transfer,
issuance, sale or disposition of Class A Shares or any security convertible into or exercisable or exchangeable for Class A Shares pursuant
to an investment in which a single strategic investor (and not an organization primarily engaged in the business of capital raising)
that is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds acquires over twenty five
percent (25%) of the fully diluted capitalization of the date thereof, provided that such securities are issued as “restricted
securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during six (6) months following the Closing Date; or (v) Class A Shares or other securities issued in connection
with a transaction with an unaffiliated third party that includes a bona fide commercial relationship entered into at arms-length (including
joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any
acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity provided that
any such transaction involves solely existing business segments or business scope that the Company is already operating in as described
in the Registration Statement, the Pricing Disclosure Package or the Final Prospectus and provided that such Class A Shares or other
securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or
permit the filing of any registration statement in connection therewith during six (6) months following the Closing Date.
3.21 Blue Sky
Qualifications. The Company shall use its commercially reasonable efforts, in cooperation with the Underwriters, if necessary,
to qualify the Shares for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or
foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Shares; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.
3.22 Reporting
Requirements. The Company, during the period when a prospectus relating to the Shares is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission
pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company
shall report the use of proceeds from the issuance of the Shares as may be required under Rule 463 under the Securities Act Regulations.
3.23 Emerging
Growth Company. From the time of initial confidential submission of a registration statement relating to the Shares with the
Commission (or, if earlier, the first date on which any oral or written communication with potential investors undertaken in reliance
on Section 5(d) of the Securities Act was made) through the date hereof, the Company has been and is an “emerging growth company,”
as defined in Section 2(a)(19) of the Securities Act.
4. Conditions
of Underwriters’ Obligations. The obligations of the Underwriters to purchase and pay for the Shares, as provided herein,
shall be subject to (i) the continuing accuracy in all material respects of the representations and warranties of the Company as
of the date hereof and as of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers
of the Company made pursuant to the provisions hereof; (iii) the performance by the Company in all material respects of its obligations
hereunder; and (iv) the following conditions:
4.1 Regulatory
Matters.
4.1.1 Effectiveness
of Registration Statement; Required Filings. The Registration Statement has been declared effective by the Commission under the
Securities Act and, at each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use
of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or
are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any)
from the Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission
in the manner and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment
providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements
of Rule 430A under the Securities Act Regulations.
4.1.2 FINRA Clearance.
On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement.
4.1.3 Exchange Stock
Market Clearance. On the Closing Date, the Company’s Class A Shares, including the Firm Shares and the Option Shares, shall
have been approved for listing on the Exchange, subject only to official notice of issuance.
4.2 Company Counsel
Matters.
4.2.1 Closing Date
Opinion of Counsel. On the Closing Date, the Underwriters shall have received the opinion and negative assurance letter of Ortoli
| Rosenstadt LLP, 366 Madison Ave, 3rd Flr, New York, NY 10017, counsel to the Company, dated the Closing Date and addressed to the Representative,
in form and substance reasonably satisfactory to the Representative.
4.2.2 Closing Date
Opinion of Indonesia Counsel. On the Closing Date, the Underwriters shall have received the opinion of Ali Burdiardjo, Nugroho,
Reksodiputro, Indonesia local counsel to the Company, dated the Closing Date and addressed to the Representative, in form and substance
reasonably satisfactory to the Representative.
4.2.3 Closing Date
Opinion of Cayman Islands Counsel. On the Closing Date, the Underwriters shall have received the opinion of Mourant Ozannes (Cayman)
LLP, Cayman Islands local counsel to the Company, dated the Closing Date and addressed to the Representative, in form and substance reasonably
satisfactory to the Representative.
4.2.4 Closing
Date Opinion of British Virgin Islands Counsel. On the Closing Date, the Underwriters shall have received the opinion of Mourant
Ozannes (BVI), British Virgin Islands local counsel to the Company, dated the Closing Date and addressed to the Representative, in form
and substance reasonably satisfactory to the Representative.
4.2.5 Option
Closing Date Opinion of Counsel. On the Option Closing Date, if any, the Underwriters shall have received the favorable opinions
of such counsels listed in Sections 4.2.1, 4.2.2, 4.2.3. and 4.24 dated the Option Closing Date, addressed to the Representative
and in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made
by such counsel in their respective opinion delivered on the Closing Date.
4.3 Comfort Letters.
4.3.1 Cold Comfort
Letter. At the time this Agreement is executed, you shall have received a cold comfort letter containing statements and information
of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain financial
information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Underwriters
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.
4.3.2 Bring-down
Comfort Letter. On the Closing Date and the Option Closing Date, you shall have received from the Auditor a letter, dated as
of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements made in the letter
furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date not more than three (3) business days
prior to the Closing Date or the Option Closing Date, as applicable.
4.4 Officers’
Certificates.
4.4.1 Officers’
Certificate. The Company shall have furnished to the Underwriters a certificate, dated the Closing Date and any Option Closing
Date (if such date is other than the Closing Date)), of its Chief Executive Officer, and its Chief Financial Officer stating that (i)
such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus
and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of
the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material
fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is
other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date
if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective date thereof
and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), did not include any untrue statement
of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
in which they were made, not misleading, (ii) since the Applicable Time, no event has occurred which should have been set forth in a
supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to the best of their knowledge
after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the
representations and warranties of the Company in this Agreement are true and correct in all material respects and the Company has complied
with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or
any Option Closing Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most
recent audited financial statements included in the Pricing Disclosure Package, any Material Adverse Effect in the financial position
or results of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a Material
Adverse Effect or a prospective Material Adverse Effect, in or affecting the condition (financial or otherwise), results of operations,
business, assets or prospects of the Company, except as set forth in the Prospectus.
4.4.2 Secretary’s
Certificate. At the Closing Date, and the Option Closing Date, if any, the Underwriters shall have received a certificate of
the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively, certifying:
(i) that each of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents is
true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors
relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all
correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company.
The documents referred to in such certificate shall be attached to such certificate.
4.5 No Material
Changes. Prior to and on the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse
Effect or development involving a prospective Material Adverse Effect in the condition or prospects or the business activities, financial
or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened
against the Company or any director or officer before or by any court or federal, state, local or foreign commission, board or other
administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects
or financial condition or income of the Company; (iii) no stop order shall have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package
and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein
in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor
the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading.
4.6 No Material
Misstatement or Omission. The Underwriters shall not have discovered and disclosed to the Company on or prior to the Closing
Date and each Option Closing Date, if any, that the Registration Statement or any amendment or supplement thereto contains an untrue
statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to state any fact which, in the opinion
of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that
the Registration Statement, the Pricing Disclosure Package or the Prospectus or any amendment or supplement thereto contains an untrue
statement of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the opinion of such counsel,
is material and is necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading.
4.7 Delivery of
Agreements.
4.7.1 Lock-Up Agreements.
On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements
from each of the persons listed in Schedule 3 hereto.
4.7.2 [Reserved].
4.7.3 Representative’s
Warrant Agreement. On the Closing Date and on each Option Closing Date, the Company shall have delivered to the Representative
executed copies of the Representative’s Warrant Agreement.
4.8 Additional
Documents. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished with
such documents and opinions as they may reasonably require for the purpose of enabling Representative Counsel to deliver an opinion to
the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the
conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Shares as herein
contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel.
5. Indemnification.
5.1 Indemnification
of the Underwriters.
5.1.1 General.
Subject to the conditions set forth below, and to the extent permitted by law, the Company agrees to indemnify and hold harmless each
Underwriter, its affiliates and each of its and their respective directors, officers, members, employees, representatives and agents
and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act (collectively the “Underwriter Indemnified Parties,” and each an “Underwriter Indemnified Party”),
against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses
reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever,
whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter
Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the Securities Act, the
Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in (i) the Registration Statement, the Pricing Disclosure
Package, the Preliminary Prospectus, or the Prospectus (as from time to time each may be amended and supplemented); (ii) any materials
or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including
any “road show” or investor presentations made to investors by the Company (whether in person or electronically); or (iii)
any application or other document or written communication (in this Section 5, collectively called “application”) executed
by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Shares under the
securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities
exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in
reliance upon, and in conformity with, the Underwriters’ Information. With respect to any untrue statement or omission or alleged
untrue statement or omission made in the Pricing Disclosure Package, the indemnity agreement contained in this Section 5.1.1 shall not
inure to the benefit of any Underwriter Indemnified Party to the extent that any loss, liability, claim, damage or expense of such Underwriter
Indemnified Party results from the fact that a copy of the Prospectus was not given or sent to the person asserting any such loss, liability,
claim or damage at or prior to the written confirmation of sale of the Shares to such person as required by the Securities Act and the
Securities Act Regulations, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver
the Prospectus was a result of non-compliance by the Company with its obligations under Section 3.3 hereof.
5.1.2 Procedure.
If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant
to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action
and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval
of such Underwriter Indemnified Party) and payment of actual expenses. Such Underwriter Indemnified Party shall have the right to employ
its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter Indemnified
Party unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company
in connection with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such
action, or (iii) such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or
them which are different from or additional to those available to the Company (in which case the Company shall not have the right to
direct the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable fees and expenses
of not more than one additional firm of attorneys selected by the Underwriter Indemnified Party (in addition to local counsel) shall
be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter Indemnified Party shall assume
the defense of such action as provided above, the Company shall have the right to approve the terms of any settlement of such action,
which approval shall not be unreasonably withheld.
5.2 Indemnification
of the Company. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity
from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions, or alleged untrue
statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus
or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters’
Information. In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus,
the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and
in respect of which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company,
and the Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions
of Section 5.1.2. The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against
the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Shares or in connection with the Registration
Statement, the Pricing Disclosure Package, or the Prospectus or any Issuer Free Writing Prospectus.
5.3 Contribution.
5.3.1 Contribution
Rights. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to
hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect
thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in
such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, from the Offering of the Shares, or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative
fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted
in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative
benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed
to be in the same proportion as the total net proceeds from the Offering of the Shares purchased under this Agreement (before deducting
expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting
discounts and commissions received by the Underwriters with respect to the Class A Shares purchased under this Agreement, as set forth
in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference to whether the
untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for
such purpose) or by any other method of allocation that does not take into account the equitable considerations referred to herein. The
amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect thereof, referred
to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses reasonably
incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions
of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total
underwriting discounts and commissions received by such Underwriter with respect to the Offering of the Shares exceeds the amount of
any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
5.3.2 Contribution
Procedure. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(“contributing party”), notify the contributing party of the commencement thereof, but the failure to so notify the contributing
party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any
such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the
commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying
party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution
on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent
of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted
by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter’s obligations
to contribute pursuant to this Section 5.3 are several and not joint.
6. Default
by an Underwriter.
6.1 Default Not
Exceeding 10% of Firm Shares or Option Shares. If any Underwriter or Underwriters shall default in its or their obligations to
purchase the Firm Shares or the Option Shares, and if the number of the Firm Shares or the Option Shares with respect to which such default
relates does not exceed in the aggregate 10% of the number of Firm Shares or the Option Shares that all Underwriters have agreed to purchase
hereunder, then such Firm Shares or the Option Shares to which the default relates shall be purchased by the non-defaulting Underwriters
in proportion to their respective commitments hereunder.
6.2 Default Exceeding
10% of Firm Shares or the Option Shares. In the event that the default addressed in Section 6.1 relates to more than 10% of the
Firm Shares or the Option Shares, you may in your discretion arrange for yourself or for another party or parties to purchase such Firm
Shares or the Option Shares to which such default relates on the terms contained herein. If, within one (1) Business Day after such default
relating to more than 10% of the Firm Shares or the Option Shares, you do not arrange for the purchase of such Firm Shares or the Option
Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another party or
parties satisfactory to you to purchase said Firm Shares or the Option Shares on such terms. In the event that neither you nor the Company
arrange for the purchase of the Firm Shares or the Option Shares to which a default relates as provided in this Section 6, this Agreement
will automatically be terminated by you or the Company without liability on the part of the Company (except as provided in Sections 3.12
and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with
respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing herein shall
relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its
default hereunder.
6.3 Postponement
of Closing Date. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting
Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the
Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect
whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in
any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriters may thereby be made necessary. The term “Underwriter”
as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been
a party to this Agreement with respect to such Class A Shares.
7. Additional
Covenants.
7.1 Board Composition
and Board Designations. The Company shall ensure that: (i) the qualifications of the persons serving as members of the Board
of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing
rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Shares
listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member of the Audit Committee
of the Board of Directors qualifies as an “audit committee financial expert,” under Regulation S-K and the listing rules
of the Exchange.
8. Effective
Date of this Agreement and Termination Thereof.
8.1 Effective
Date. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered
counterparts of such signatures to the other party.
8.2 Termination.
The Underwriters shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international
event or act or occurrence has materially disrupted, or in the Representative’s opinion will in the immediate future materially
disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange, the NYSE American LLC,
the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market shall have been suspended or materially limited,
or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required
by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United States shall have
become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York
State or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the
United States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake,
theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the Representative’s
opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option Shares; or (vii) if the Company is in material
breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative shall have become aware
after the date hereof of such a Material Adverse Effect in the conditions or prospects of the Company, or such adverse material change
in general market conditions as in the Representative’s judgment would make it impracticable to proceed with the offering, sale
and/or delivery of the Shares or to enforce contracts made by the Underwriters for the sale of the Shares.
8.3 Expenses.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section
6.2 above, in the event that this Agreement is terminated prior to the Closing Date for any reason whatsoever, within the time specified
herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual
and accountable out-of-pocket documented expenses related to the transactions contemplated herein then due and payable (including the
out-of-pocket and documented fees and disbursements of Representative Counsel) up to $150,000, and upon demand the Company shall pay
the full amount thereof up to the cap to the Representative on behalf of the Underwriters; provided, however, that such expense cap in
no way limits or impairs the indemnification and contribution provisions of this Agreement.
8.4 Survival of
Indemnification. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force
and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement
or any part hereof.
8.5 Representations,
Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation
made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or
directors or any person controlling the Company or (ii) delivery of and payment for the Shares.
9. Miscellaneous.
9.1 Notices.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by electronic mail (email) and confirmed and shall be deemed
given when so delivered or sent via email and confirmed or if mailed, two (2) days after such mailing.
If to the Representative:
A.G.P./Alliance Global Partners
590 Madison Avenue, 28th Floor
New York, New York 10022
Attn: Thomas Higgins
Email: thiggins@allianceg.com
with a copy (which shall
not constitute notice) to:
Lewis Brisbois Bisgaard & Smith LLP
45 Fremont Street, 30th Floor
San Francisco, CA 94105
Attention: John Yung
Email: John.Yung@lewisbrisbois.com
If to the Company:
BrilliA Inc
220 Orchard Road
Unit 05-01, Midpoint Orchard
Singapore 238852
Attention: Mr. Kendrew Hartanto, Chief Executive Officer
Email:with a copy (which shall not constitute notice) to:
Ortoli Rosenstadt LLP
366 Madison Avenue, 3rd Floor
New York, NY 10017
Attention:
William S. Rosenstadt, Esq.
Mengyi “Jason” Ye, Esq.
Yarona Yieh, Esq.
9.2 Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Agreement.
9.3 Amendment.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.
9.4 Entire Agreement.
This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.
9.5 Binding Effect.
This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the
controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term “successors and assigns” shall not include
a purchaser, in its capacity as such, of securities from any of the Underwriters.
9.6 Governing
Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance with
the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and
irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive
jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served
by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address
set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any
action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the
other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders
and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
9.7 Execution
in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement,
and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other
parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and
sufficient delivery thereof.
9.8 Waiver, etc..
The failure of any of the parties hereto to at any time to enforce any of the provisions of this Agreement shall not be deemed or construed
to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of
any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or
non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the
party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.
[Signature Page Follows]
If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between us.
| |
Very truly yours, |
| |
|
| |
BrilliA Inc |
| |
|
| |
By: |
/s/ Kendrew Hartanto |
| |
Name: |
Kendrew Hartanto |
| |
Title: |
CEO |
Confirmed as of the date first written above
mentioned, on behalf of itself and as
Representative of the several Underwriters
named on Schedule 1 hereto:
| A.G.P./ALLIANCE GLOBAL PARTNERS |
|
| |
|
| By: |
/s/
Thomas J. Higgins |
|
| Name: |
Thomas J. Higgins |
|
| Title: |
Managing Director |
|
[SIGNATURE PAGE]
BrilliA – UNDERWRITING AGREEMENT
SCHEDULE 1
| Underwriter | |
Total Number
of Firm
Shares to be
Purchased | | |
Number of Option
Shares to be
Purchased if the
Over-Allotment
Option is Fully
Exercised by the
Representative | |
| A.G.P./Alliance Global Partners | |
| 2,500,000 | | |
| 375,000 | |
| TOTAL | |
| 2,500,000 | | |
| 375,000 | |
SCHEDULE 2-A
Pricing Information
Number of Firm Shares: 2,500,000
Number of Option Shares: 375,000
Public Offering Price per Firm Share: $4.00
Underwriting Discount per Firm Share resold to prior Shareholders of
the Company: N/A
Underwriting Discount per Firm Share resold to new investors: $0.28
Proceeds to Company per Firm Share (before expenses): $3.72
SCHEDULE 2-B
Issuer General Use Free Writing Prospectus
Filed on September 30, 2024
Filed
Pursuant to Rule 433
Registration Statement
No. 333-282056
Issuer Free Writing
Prospectus dated September 30, 2024
Relating to Preliminary
Prospectus dated
September 18,
2024
Free Writing Prospectus
BrilliA
Incorporated
2,500,000
Class A Ordinary Shares
This free writing
prospectus relates to the initial public offering of ordinary shares of BrilliA Incorporated (the “Company”) and should be
read together with the preliminary prospectus dated September 18, 2024 (the “Preliminary Prospectus”) that was included in
Amendment No. 1 to the Registration Statement on Form F-1 (File No. 333-282056), which can be accessed through the following web link:
https://www.sec.gov/Archives/edgar/data/2000230/000121390024079743/ea0200081-14.htm
The issuer has
filed a registration statement (including a preliminary prospectus) on Form F-1 (File No. 333-282056) with the SEC for the offering to
which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents
the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free
by visiting EDGAR on the SEC Website www.sec.gov. Alternatively, the Company and any underwriter or any dealer participating in the offering
will arrange to send you the prospectus if you request it by contacting Karen Mu via email at kmu@allianceg.com, by phone at 212-624-2138.
Vertically Integrated Solutions for Women’s Lingerie Brands BrilliA Incorporated Corporate Presentation September 2024 NYSE American: BRIA (pending approval)
Forward - Looking Statements You must read the following disclaimer before continuing . The following disclaimer applies to the Presentation, related materials and any oral Presentation by the Company (as defined below) or any person on its behalf, any question and answer session that may follow the oral Presentation, and any material distributed in connection therewith (collectively, the “Presentation”) to be accessed from this page or otherwise viewed because of such access and you are therefore advised to read this disclaimer page carefully before viewing the Presentation . In accessing the Presentation, you acknowledge and agree to be bound by the following terms and conditions . This Presentation has been prepared by BrilliA Incorporated (the “Company” or “BrilliA”) solely for informational purposes and is intended only for those persons to whom it is delivered personally by or on behalf of the Company, without regard to the specific investment objectives, financial situation and particular needs of any person . The information included herein in this Presentation has not been independently verified . No representations, warranties or undertakings, express or implied, are made by Company or any of its affiliates, advisers or representatives or the underwriters as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this Presentation . By viewing or accessing the information contained in this Presentation, you acknowledge and agree that none of Company or any of its affiliates, advisers or representatives or the underwriters accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this Presentation or otherwise arising in connection with the Presentation . The information presented or contained in this Presentation is subject to change without notice and its accuracy is not guaranteed . None of the Company or any of its affiliates, advisers or representatives or the underwriter make any undertaking to update any such information subsequent to the date hereof . This Presentation should not be construed as legal, tax, investment or other advice . This Presentation contains statements that reflect the Company’s intent, beliefs or current expectations about the future . These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,” “intends,” or words of similar meaning . These forward looking statements are not guarantees of future performance and are based on a number of assumptions about the Company’s operations and other factors, many of which are beyond the Company’s control, and accordingly, actual results may differ materially from these forward looking statements . Caution should be taken with respect to such statements and you should not place undue reliance on any such forward looking statements . The Company or any of its affiliates, advisers or representatives or the underwriter has no obligation and does not undertake to revise forward looking statements to reflect newly available information, future events or circumstances . No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this Presentation should or will be achieved . The Presentation is being accessed by you in an electronic form . You are reminded that any component of the Presentation, including any documents included in the Presentation, may be altered or changed during the process of transmission and consequently none of the Issuer, the underwriters or any person who controls any of them, or any director, officer, employee or agent of any of them, or any affiliate of any such person accepts any liability or responsibility . This Presentation does not constitute an offer to sell or an invitation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else . No part of this Presentation shall form the basis of or b e relied upon in connection with any contract or commitment whatsoever . Specifically , these materials do not constitute a “prospectus” within the meaning of the U . S . Securities Act of 1933 , as amended, and the regulations enacted thereunder . This Presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company and is qualified in its entirety by reference to the detailed information in the prospectus relating to the proposed offering . Any decision to purchase the Company’s securities in the proposed offering should b e made solely on the basis of the information contained in the prospectus relating to the proposed offering . In evaluating its business, the Company uses or may use certain non - GAAP measures as supplemental measures to review and assess its operating and financial performance . These non - GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating and financial performances, investors should not consider them in isolation, or as a substitute for any consolidated statement of operations data prepared in accordance with U . S . GAAP . THE INFORMATION CONTAINED IN THIS DOCUMENT IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION . THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER . You are responsible for protecting against viruses and other destructive items . Your use of this website and the Presentation is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature . Any forwarding, distribution or reproduction of this Presentation in whole or in part is unauthorized .
The Offering BRIA NYSE American $4.00 to $5.00 per Class A Share Proposed Trading Symbol Proposed Exchange Offering Price Transfer Agent # of Class A Shares Offered # of Class A Shares Outstanding Following Offering VStock Transfer, LLC 2,500,000 25,000,000 Use of Proceeds 1. Development of Digital Marketing Platform 2. Research and Development 3. Expansion of B2B Business 4. General Working Capital and Corporate Purposes
About BrilliA BrilliA sources, designs, and delivers high - quality, competitively priced, and sustainable lingerie from Indonesia, Thailand, and China to be marketed to major brands, primarily in North America and Europe . The company’s operating subsidiaries are : BRA PRO LIMITED (BRA PRO) BrilliA’s sales and marketing entity, incorporated in 2011. PT MIRAE ASIA PACIFIC (MAP) Offers designs for and controls the execution of the orders received by BRA PRO, incorporated in 2015. BrilliA SINGAPORE An investment holding company incorporated in 2023. BrilliA aims to launch its own premium lingerie brand, DIANA, soon. DIANA will initially target younger consumers in the Indonesia and SE Asia markets, where there is a great opportunity to introduce high - quality and value - driven lingerie options. Our operations are being supported by over 170 associates .
We source, create designs, procure materials, and detailed technical specifications for external manufacturing facilities Overview Vertically integrated services allow brand owners to reduce corporate headcount We do not own manufacturing facilities, leading to a reduction in costs and increasing our profitability Specializes in intricate, skill - intensive products, elevating overall value delivered to customers Does NOT source cotton and other raw materials obtained from forced labor in China’s Xinjiang Uyghur Autonomous Region Provides products and services to major lingerie brands and retailers worldwide
Products include bras, bodysuits, panties, and related women’s intimate apparel. Extensive range of product styles designed for diverse price points and sizes. Provides products with international standard qualities from independent external manufacturers that meet international ethical compliance. Product Portfolio For the year ended March 31 2023 2024 Sales of garments: % of revenue % of revenue 91.7% 92.1% Brassiere 5.3% 7.0% Bodysuit 1.4% 0.4% Panty 0.4% — Swimsuit 0.6% — Dress 0.2% — Others 99.6% 99.5% 0.4% 0.5% Service rendered 100.0% 100.0% Total revenue
Our Customers Over 20 World Famous Brands including
Design & Sourcing Strong design and sourcing capability with a track record of turning design concepts into finished samples within targeted lead times. One - Stop Multiple Solutions Vertically integrated one - stop apparel supply chain services operation ensures high - quality, cost - effective solutions. Robust Relationships Strong, stable relationship with key customers in the US, Europe, and Canada who notify the company of production needs in advance and refer prospective customers. Decades Experience Management possesses decades of lingerie industry experience and positions the company for continued growth and development. Competitive Strengths
Market innovative, value - driven, and high - quality lingerie products for younger consumers, while promoting body positivity. About DIANA We plan to diversify the Group’s businesses through our premium lingerie brand, DIANA, a line of products marketed directly to consumers. With the launch of DIANA, we aim to: Expand our product portfolio to include sleepwear, babywear, activewear, and period panties. Obtain higher margins by selling directly to customers. Reinforce the ex1-1 of our design capabilities to B2B customers. Target consumers online, enhancing our direct customer engagement and brand awareness.
About DIANA With the launch of DIANA, we aim to establish boutique retail locations in: In addition to these retail locations, we plan on introducing pop up stores, and kiosks, as well as expanding online through our Website, Instagram, and Marketplaces, and utilizing influencers to capture additional market share and increase brand visibility. DIANA Flagship Store - External DIANA Flagship Store - Interior DIANA Pop - Up Store Singapore Indonesia ASEAN Countries Europe
Industry Outlook: 2022 - 2030 According to Grand View Research (Oct 2023) Global Lingerie Market $88.32 Billion Expected to grow by a CAGR 5.7% through 2030 SE Asia manufacturers expected to increase their focus on products that embrace more diverse body types. Global growth is expected to be driven by the rising purchasing power of women, with brands that focus on sustainability and ethical practices gaining a competitive edge. SE Asia Lingerie Market $3.42 Billion Expected to grow by a CAGR 5.3% through 2030 Indonesia Lingerie Market $1.06 Billion Expected to reach $1.54B by 2030
Growth Strategies Recruit additional designers to expand product mix capabilities. Diversifying on new products to increase our revenue. Add sleepwear, activewear, period panties, mastectomy bras and baby wear to the product portfolio. Develop DIANA in - house premium brand and market to the younger demographic at retail outlets in Indonesia, SE Asia, and via leading online and social media platforms. Leverage DIANA’s direct - to - customer sales to produce improved company margins. Add new customers by creating an accessible e - commerce platform and enhanced digital marketing strategies. Expand business and operations through joint ventures, acquisitions, and/or strategic alliances in Southeast Asia.
Mr. Kendrew Hartanto Chief Executive Officer Our Team of Industry Experts An industry veteran with 28 years in women’s fashion. Expertise in sourcing, design, and production across multiple countries including Indonesia, PRC, and Thailand. Holds a Bachelor of Science Degree in Finance and Marketing from the University of Southern California. Mr. Salim Podiono Co - Founder, Executive Director, & Chairman Visionary leader with a 30 - year career in the garment industry recognized expertise in manufacturing, marketing, and distribution. Holds a Master’s Degree in Finance from George Washington University. Mr. Koh Wah Seng Philip Chief Financial Officer Over 25 years of experience in operational accounting with various listed companies and multi - national corporations in Singapore. Holds Bachelor of Business Degree in Accounting from Monash University, Australia.
Mr. Karl - Heinz Barth Independent Director Nominee, Compensation Committee Chairman Nominee Renowned expert in underwear industry, with a career spanning over 25 years at Triumph International. Our Board of Independent Directors Mr. Kok Poh Fui Independent Director Nominee, Audit Committee Chairman Nominee Executive Director and former CFO of Xin Hwa Holdings Berhad. Fellow of the Association of Chartered Certified Accountants and member of the Malaysian Institute of Accountants. Mr. Gary Kronfeld Independent Director Nominee, Nomination Committee Chairman Nominee Served as VP and CEO for SPIRITE INDUSTRIES INC, which designed, manufactured, sourced, and distributed branded and private label intimate apparel to major retailers throughout the US, Canada, Mexico, and the Caribbean. Ms. Iming Bahari Independent Director Nominee Seasoned professional with 30 years of experience in human resources. Currently serves as VP of Human Capital Management at Mandai Wildlife Group.
Financial Information Fiscal Years ended March 31, 2023, vs. March 31, 2024 $51,613,000 $55,756,000 $7,821,000 $8,432,000 $4,173,000 $3,146,000 $0 $10,000,00 0 $50,000,00 0 $40,000,00 0 $30,000,00 0 $20,000,00 0 $60,000,00 0 2023 2024 Revenue Gross Profit Net Income
Financial Information STATEMENTS OF PROFIT OR LOSS 2024 2023 For the year ended March 31, USD’000 USD’000 55,756 51,613 Revenue (47,324) (43,792) Cost of revenue 8,432 7,821 Gross profit Operating expenses * * Depreciation of property, plant and equipment (208) (170) Employee benefit expense (4,339) (2,645) Other expenses (236) (18) Net loss on impairment of financial assets (4,783) (2,833) Total operating expenses 119 10 Other income 119 10 Total other income (622) (825) Income tax expense 3,146 4,173 Net Income Profit from operation 4,988 3,649 Profit before income taxes 4,998 3,768
Financial Information STATEMENTS OF FINANCIAL POSITION 2023 2024 USD’000 USD’000 ASSETS Non - current assets 2 3 Property, plant and equipment, net 837 — Deferred offering costs 839 3 Total non - current assets Current assets 7,093 5,732 Inventories 11,993 7,457 Trade and other receivables 460 100 Amount due from related parties 5,954 8,913 Cash and cash equivalents 25,500 22,202 Total current assets 26,339 22,205 Total Assets 2023 2024 USD’000 USD’000 LIABILITIES AND EQUITY Current liabilities 16,803 14,015 Trade and other payables 57 8 Amount due to a shareholder 2,305 1,683 Income tax payable 19,165 15,706 Total current liabilities 19,165 15,706 Total liabilities Capital and reserves 50 1 Share capital 7,124 6,498 Retained earnings 7,174 6,499 Total shareholders’ equity 26,339 22,205 Total liabilities and equity
IPO Structure USE OF PROCEEDS Research & Development We intend to use 10 % of the net proceeds to research new product segments and to explore new designs within the brasserie segment . Development & Marketing of DIANA We intend to use 15 % of the net proceeds for the development and marketing of the DIANA brand and related products . We plan to target both online and offline retail segments . For the offline retail segment, we intend to seek strategic locations with busy customer traffic to open one flagship retail outlet in Indonesia, one additional outlet in Europe and a number of pop - up stores/kiosks . We also intend to market the products under the DIANA brand in virtual retailing via our own online selling platform . B2B Business Expansion We intend to use 35 % of the net proceeds for further expansion of our existing B 2 B business by exploring other garment product segments such as scrub, uniforms, swimwear, panties, and in technical equipment, which will require further investment to further upgrade product selection that can be offered to the customers . The expansion will enable the Company to do cross - sale of products to national brands and retailers . Working Capital & Operations We plan to use 40 % of the net proceeds for additional general working capital and business expansion . R&D 10% Development & Marketing of DIANA 15% B2B Business Expansion 35% Working Capital & Operations 40%
Asset Light Company Maintaining minimal ownership of physical assets enable us to allocate our valuable resources on our core competencies In - House Brand Launch Upcoming launch of DIANA brand has the potential to generate improved margins Industry Expert Team Highly accomplished senior management with a top track record The business has generated growth over the years through existing cash flows Profitability Major Lingerie Clients We provide sourcing and design services to major lingerie brands Robustly Growing Market Robust lingerie industry growth projected both in SE Asia and globally Investment Highlights Global Expansion Plans Product/global expansion plans in progress Established Industry Relations Stable relationships with over 20 World Famous Brands
Thank You! Company Contact BrilliA Incorporated 220 Orchard Road, Unit 05 - 01, Midpoint Orchard Singapore 238852 info@brilliaincorporated.com Investor Relations Scott Powell, President New York, NY 10036 info@skylineccg.com | +1.646.893.5835 A.G.P./Alliance Global Partners Skyline Corporate Communications Group, LLC 590 Madison Avenue, 28th Floor 1177 Avenue of the Americas, 5th Floor, New York, NY 10022 kmu@allianceg.com Underwriter Karen Mu
SCHEDULE 3
List of Lock-Up Parties
| Lock-Up Parties |
|
Term of Lock Up |
| Salim Podiono |
|
180 days |
| Nursalim Podiono |
|
180 days |
| Shim Siang Fan |
|
180 days |
| Kendrew Hartanto |
|
180 days |
| Koh Wah Seng Philip |
|
180 days |
| Kok Poh Fui |
|
180 days |
| Karl-Heinz Barth |
|
180 days |
| Gary H. Kronfeld |
|
180 days |
EXHIBIT A
Representative’s Warrant Agreement
EXHIBIT B
Lock-Up Agreement
Exhibit 4.1
THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE
HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS WARRANT
AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE
EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) A.G.P./ALLIANCE GLOBAL PARTNERS OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION
WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF A.G.P./ALLIANCE GLOBAL PARTNERS OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.
PURCHASE WARRANT
FOR THE PURCHASE
OF [●] SHARES OF CLASS A ORDINARY SHARES
OF
BRILLIA INC
| Warrant No.: [●] |
|
Original Issue Date: November 29, 2024 |
BrilliA Inc, a corporation
formed under the laws of Cayman Islands (the “Company”), hereby certifies that pursuant to that certain Underwriting Agreement
dated November 26, 2024 (as may be amended from time to time, the “Underwriting Agreement”) by and between the Company and
A.G.P./Alliance Global Partners, for value received, A.G.P./Alliance Global Partners or its registered assigns (the “Holder”),
is entitled to purchase from the Company up to a total of [•] shares of the Company’s Class A ordinary shares (each such share,
a “Warrant Share” and all such shares, the “Warrant Shares”), at any time and from time to time from and after
the 180th day (the “Commencement Date”) from the date of effectiveness of that certain registration statement on
Form F-1 (File No. 333-282056) filed by the Company (the “Effective Date”), in accordance with FINRA Rule 5110(e)(1), and
through and including the five (5) year anniversary of the date of effectiveness of that certain registration statement on Form F-1 (File
No. 333-282056), which such date is November 19, 2029, which such date shall not be more than five years from the commencement of sales
of the public offering pursuant to that certain registration statement on Form F-1 (File No. 333-282056) filed by the Company (the “Expiration
Date”), and subject to the following terms and conditions:
Section 1. Definitions. As used in this
Warrant, the following terms shall have the respective definitions set forth in this Section 1.
“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 144.
“Business Day”
means any day except Saturday, Sunday and any day which is a federal legal holiday or a day on which banking institutions in the State
of New York are authorized or required by law or other governmental action to close.
“Class A Ordinary
Shares” means the Class A Ordinary Shares of the Company, par value $0.0001 per share, and any securities into which such Class
A Ordinary Shares may hereafter be reclassified or for which it may be exchanged as a class.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended.
“Exercise Price”
means $5.20, subject to adjustment in accordance with Section 9.
“Fundamental Transaction”
means any of the following: (1) the Company effects any merger or consolidation of the Company with or into another Person, (2) the Company
effects any sale of all or substantially all of its assets in one or a series of related transactions, (3) any tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Class A Ordinary Shares are permitted to tender
or exchange their shares for other securities, cash or property, or (4) the Company effects any reclassification of the Class A Ordinary
Shares or any compulsory share exchange pursuant to which the Class A Ordinary Shares are effectively converted into or exchanged for
other securities, cash or property.
“New York Courts”
means the state and federal courts sitting in the City of New York, Borough of Manhattan.
“Original Issue Date”
means the Original Issue Date first set forth on the first page of this Warrant.
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Rule 144”
means Rule 144 promulgated by the Securities and Exchange Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Securities and Exchange Commission having substantially the same
effect as such Rule.
“Securities Act”
means the Securities Act of 1933, as amended.
“Subsidiary”
means any “significant subsidiary” as defined in Rule 1-02(w) of Regulation S-X promulgated by the Securities and Exchange
Commission under the Exchange Act.
“Trading Day”
means (i) a day on which the Class A Ordinary Shares are traded on a Trading Market, or (ii) if the Class A Ordinary Shares are not quoted
on any Trading Market, a day on which the Class A Ordinary Shares are quoted in the over-the-counter market as reported by the OTC Markets
Group, Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that
the Class A Ordinary Shares is not listed or quoted as set forth in (i) or (ii) hereof, then Trading Day shall mean a Business Day.
“Trading Market”
means whichever of the New York Stock Exchange, the NYSE American, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ
Capital Market, OTC Bulletin Board, or the OTC Markets Group, Inc. OTCQX or OTCQB tier on which the Class A Ordinary Shares are listed
or quoted for trading on the date in question.
“Warrant Shares”
means the Class A Ordinary Shares issuable upon exercise of this Warrant.
Section 2. Registration of Warrant. The Company shall register
this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of
the record Holder hereof as below.
(a) “Piggy-Back”
Registration. Unless all of the Class A Ordinary Shares underlying this Warrant (collectively, the “Registrable Securities”)
are included in an effective registration statement with a current prospectus, the Holder shall have the right, commencing on the date
that this Warrant becomes exercisable to include the remaining Registrable Securities as part of any other registration of securities
filed by the Company (other than in connection with a transaction contemplated by Rule 145 promulgated under the Act or pursuant to Form
S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account
of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of
Class A Ordinary Shares of Registrable Securities which may be included in the registration statement because, in such underwriter(s)’
judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be
obligated to include in such registration statement only such limited portion of the Registrable Securities with respect to which the
Holder requested inclusion hereunder as the underwriter shall reasonably permit; and further provided that no such piggy-back rights shall
exist for so long as the Registrable Securities (which term shall include those paid as consideration pursuant to the cashless exercise
provisions of this Warrant) may be sold pursuant to Rule 144 of the Act without restriction. Any exclusion of Registrable Securities shall
be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought
to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company has
first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration
Statement or are not entitled to pro rata inclusion with the Registrable Securities. In the event of such a proposed registration, the
Company shall furnish the then Holders of outstanding Registrable Securities with not less than fifteen (15) days written notice prior
to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable
Securities shall exercise the “piggy-back” rights provided for herein by giving written notice, within seven (7) days of the
receipt of the Company’s notice of its intention to file a registration statement. Except as otherwise provided in this Warrant,
there shall be no limit on the number of times the Holder may request registration under this Section 2 (a).
(b) Demand
Registration Rights. Solely in the event there is not then a current registration statement concerning the resale of the Registrable
Securities, at any time commencing on the date that this Warrant becomes exercisable until five (5) years from the Effective Date, the
Holder is entitled to one “demand” registration right at the Company’s sole expense and an additional “demand”
registration right at the Holder’s expense. Upon receipt of a demand registration request from the Holder, the Company shall prepare
and file with the SEC a required registration statement (the “Required Registration Statement”) concerning the resale
of all of the Registrable Securities. The Required Registration Statement shall be on Form F-3 if available for such a registration and
if unavailable, the Company shall register the resale of the Registrable Securities on Form F-1 or another appropriate form reasonably
acceptable to the Holder and undertake to register the resale of the Registrable Securities on Form F-3 as soon as such form is available,
provided that the Company shall maintain the effectiveness of all Registration Statements then in effect until such time as a Registration
Statement on Form F-3 covering the resale of all of the Registrable Securities has been declared effective by the SEC and the prospectus
contained therein is available for use. Within ten (10) days after receiving written notice from the Holder, the Company shall give notice
to the other Holders of the Warrants advising that the Company is proceeding with such registration statement and offering to include
therein Warrants of such other Holders. The Company shall not be obligated to any such other Holder unless such other Holder shall accept
such offer by notice in writing to the Company within five (5) days thereafter. The Company shall use its best efforts to have such Required
Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this Warrant, declared effective
by the SEC as soon as practicable. The Company shall pay the costs and expenses thereof, for one time only, which costs and expenses shall
include “Blue Sky” fees for counsel for the Underwriter and “Blue Sky” filing fees to qualify the Warrants in
those jurisdictions requested by the Holder.
(c) Expenses
of Registration. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section
2 (b) hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders
to represent them in connection with the sale of the Registrable Securities.
(d) Indemnification.
The Company shall indemnify, to the fullest extent permitted by applicable laws, the Holder(s) of the Registrable Securities to be sold
pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of
the Act or Section 20 (a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them
may become subject under the Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent
and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriter contained in Section
6 of the Underwriting Agreement.
(e) Exercise
of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or
after the initial filing of any registration statement or the effectiveness thereof.
(f) Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the registration statement filed by the Company shall
furnish to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling
security holders.
(g) Damages.
Should the registration or the effectiveness thereof required by Section 2 hereof be delayed by the Company or the Company otherwise fails
to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled
to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the
continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.
Section 3. Transfers. (a) The Company
shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment
attached hereto duly completed and signed, to the Company at its address specified herein. Upon any such registration of transfer, a new
Warrant to purchase Class A Ordinary Shares, in substantially the form of this Warrant (any such new Warrant, a “New Warrant”),
evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion
of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.
This Warrant may not be sold,
transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the securities by any person for a period of 180 days beginning on the date of effectiveness
of that certain registration statement on Form F-1 (File No. 333-282056) filed by the Company, except as provided in FINRA Rule 5110(e)(2).
4. Exercise
and Duration of Warrants. This Warrant shall be exercisable by the registered Holder at any time and from time to time from and after
the 181st day immediately following the date of effectiveness of that certain registration statement on Form F-1 (File No. 333-282056)
filed by the Company, in accordance with FINRA Rule 5110(e)(1), and through and including the Expiration Date. At 5:30 p.m., New York
City time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The
Company may not call or redeem any portion of this Warrant without the prior written consent of the affected Holder.
5. Delivery of Warrant
Shares.
(a) To
effect exercises hereunder, the Holder shall not be required to physically surrender this Warrant unless the aggregate Warrant Shares
represented by this Warrant is being exercised. Upon delivery of the Exercise Notice (in the form attached hereto) to the Company (with
the attached Warrant Shares Exercise Log) at its address for notice set forth herein and upon payment of the Exercise Price multiplied
by the number of Warrant Shares that the Holder intends to purchase hereunder, the Company shall promptly (but in no event later than
two Trading Days after the Date of Exercise (as defined herein)) issue and deliver to the Holder, a certificate for the Warrant Shares
issuable upon such exercise. The Company shall, upon request of the Holder and subsequent to the date on which a registration statement
covering the resale of the Warrant Shares has been declared effective by the Securities and Exchange Commission, use its reasonable best
efforts to deliver Warrant Shares hereunder electronically through the Depository Trust & Clearing Corporation or another established
clearing corporation performing similar functions, if available, provided, that, the Company may, but will not be required to change its
transfer agent if its current transfer agent cannot deliver Warrant Shares electronically through the Depository Trust Corporation. A
“Date of Exercise” means the date on which the Holder shall have delivered to the Company: (i) the Exercise Notice (with the
Warrant Exercise Log attached to it), appropriately completed and duly signed and (ii) payment of the Exercise Price for the number of
Warrant Shares so indicated by the Holder to be purchased.
(b) If
by the second Trading Day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner required
pursuant to Section 5(a), then the Holder will have the right to rescind such exercise; provided, that the Holder shall be required to
return any Warrant Shares subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise
Price paid to the Company for such Warrant Shares and the restoration of Holder’s right to acquire such Warrant Shares pursuant
to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).
(c) If
by the second Trading Day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner required
pursuant to Section 5(a) (other than as a result of failure of the Holder to timely deliver the aggregate Exercise Price, unless the Warrant
is validly exercised by means of a cashless exercise), and if after such second Trading Day and prior to the receipt of such Warrant Shares,
the Holder purchases (in an open market transaction or otherwise) Class A Ordinary Shares to deliver in satisfaction of a sale by the
Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall
(1) pay in cash to the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the Class A Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (A) the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue by (B) the closing bid price of the Class A Ordinary
Shares on the Date of Exercise and (2) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number
of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder
the number of Class A Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations
hereunder; provided, that the Holder shall have no right to any such amount hereunder to the extent the failure of the Company to deliver
such Warrant Shares is caused by the Holder’s failure to provide complete information required to be provided by the Holder to the
Company hereunder or the inaccuracy of any such information. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
(d) The
Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective
of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation
of law by the Holder or any other Person, and irrespective or any other circumstance which might otherwise limited such obligation of
the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder’s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver certificates representing Warrant Shares upon exercise
of the Warrant as required pursuant to the terms hereof.
6. Charges,
Taxes and Expenses. Issuance and delivery of Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder
for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required
to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result
of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
7. Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall
not include a surety bond), if requested. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested
as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent
to the Company’s obligation to issue the New Warrant.
8. Reservation
of Warrant Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve and keep available out
of the aggregate of its authorized but unissued and otherwise unreserved Class A Ordinary Shares, solely for the purpose of enabling it
to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable
upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of Persons other than the
Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable
and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly authorized,
validly issued and fully paid and nonassessable.
9. Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from
time to time as set forth in this Section 9.
(a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Class A Ordinary
Shares or otherwise makes a distribution on any class of capital stock that is payable in Class A Ordinary Shares (which, for avoidance
of doubt, shall not include any Class A Ordinary Shares issued by the Company upon exercise of this Warrant or any other Warrants), (ii)
subdivides outstanding Class A Ordinary Shares into a larger number of shares, or (iii) combines (including by way of reverse stock split)
outstanding Class A Ordinary Shares into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of Class A Ordinary Shares outstanding immediately before such event and of which
the denominator shall be the number of Class A Ordinary Shares outstanding immediately after such event. Any adjustment made pursuant
to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination.
(b) Fundamental
Transactions. If, at any time while this Warrant is outstanding there is a Fundamental Transaction, then the Holder shall have the
right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have
been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Class A Ordinary Shares in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Class A Ordinary Shares are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. At the Holder’s
option and request, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant
substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Holder’s right to purchase
the Alternate Consideration for the aggregate Exercise Price upon exercise thereof. The terms of any agreement pursuant to which a Fundamental
Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this paragraph
(b) and ensuring that the Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous
to a Fundamental Transaction.
(c) Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to this Section 9, the number of Warrant Shares
that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the
aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price
in effect immediately prior to such adjustment.
(d) Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable. The number of
Class A Ordinary Shares outstanding at any given time shall not include shares owned or held by or for the account of the Company, and
the disposition of any such shares shall be considered an issue or sale of Class A Ordinary Shares.
(e) Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will promptly compute
such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement
of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant
(as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment
is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s
Transfer Agent.
(f) Notice
of Corporate Events. If the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect
of its Class A Ordinary Shares, including without limitation any granting of rights or warrants to subscribe for or purchase any capital
stock of the Company or any Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval
for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction (but only to the
extent such disclosure would not result in the dissemination of material, non-public information to the Holder) at least 10 calendar days
prior to the applicable record or effective date on which a Person would need to hold Class A Ordinary Shares in order to participate
in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to ensure that the Holder
is given the practical opportunity to exercise this Warrant prior to such time so as to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice.
10. Payment
of Exercise Price. The Holder may pay the Exercise Price in one of the following manners:
| (a) | Cash Exercise. The Holder may deliver immediately available funds; or |
| (b) | Cashless Exercise. The Holder may notify the Company in an Exercise Notice of its election to utilize
cashless exercise, in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: |
X = Y [(A-B)/A]
where:
X = the number of Warrant Shares
to be issued to the Holder in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than
a cashless exercise.
Y = the number of Warrant Shares
with respect to which this Warrant is being exercised.
A = the closing price for one
Class A Ordinary Share as reported on the Trading Market for the Trading Day immediately prior to the date of exercise.
B = the Exercise Price.
For purposes of Rule 144 promulgated
under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued.
If Warrant Shares are issued
in such a cashless exercise, the Company and the Holder each acknowledge and the Company agrees that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees
not to take any position contrary to this Section 10(b).
11. Limitations
on Exercise. Notwithstanding anything to the contrary contained herein, the number of Warrant Shares that may be acquired by the Holder
upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure that, following
such exercise (or other issuance), the total number of Class A Ordinary Shares then beneficially owned by such Holder and its Affiliates
and any other Persons whose beneficial ownership of Class A Ordinary Shares would be aggregated with the Holder’s for purposes of
Section 13(d) of the Exchange Act, does not exceed 4.99% of the total number of issued and outstanding Class A Ordinary Shares (including
for such purpose the Class A Ordinary Shares issuable upon such exercise). For such purposes, beneficial ownership shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. This provision shall not restrict
the number of Class A Ordinary Shares which a Holder may receive or beneficially own in order to determine the amount of securities or
other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9 of this Warrant.
This restriction may not be waived. Notwithstanding anything to the contrary contained in this Warrant, (a) no term of this Section may
be waived by any party, nor amended such that the threshold percentage of ownership would be directly or indirectly increased, (b) this
restriction runs with the Warrant and may not be modified or waived by any subsequent holder hereof and (c) any attempted waiver, modification
or amendment of this Section will be void ab initio.
12. No
Fractional Shares. No fractional shares of Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu
of any fractional shares which would, otherwise be issuable, the Company shall, at its election, either pay cash equal to the product
of such fraction multiplied by the closing price of one Warrant Share as reported by the applicable Trading Market on the date of exercise
or round to the nearest whole share.
13. Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing
and shall be deemed given in the manner set forth in Section 9.1 of the Underwriting Agreement.
14. Warrant
Agent. The Company shall serve as warrant agent under this Warrant. Upon 10 days’ notice to the Holder, the Company may appoint
a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant
agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this
Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be
mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.
15. Miscellaneous.
(a) This
Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the
preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or
equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the
Holder and their successors and assigns. The foregoing sentence shall be subject to the restrictions on waivers and amendments set forth
in Section 11 of this Warrant.
(b) All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.
Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of this Warrant and the transactions
herein contemplated (“Proceedings”) (whether brought against a party hereto or its respective Affiliates, employees or agents)
shall be commenced exclusively in the New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York (the New York Supreme Court, County of New York, and the United States District Court for the Southern District of
New York collectively the “New York Courts”), and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any New York Court, or that
such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service
of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Warrant or
the transactions contemplated hereby. If either party shall commence a Proceeding to enforce any provisions of this Warrant, then the
prevailing party in such Proceeding shall be reimbursed by the other party for its attorney’s fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such Proceeding.
(c) The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the
provisions hereof.
(d) In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Warrant.
(e) Prior
to exercise of this Warrant, the Holder hereof shall not, by reason of being a Holder, be entitled to any rights of a stockholder with
respect to the Warrant Shares.
(f) No
provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Class A
Ordinary Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.
********************
(Signature
Page Follows)
IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
| |
BrilliA Inc |
| |
|
| |
By: |
|
| |
Name: |
Kendrew Hartanto |
| |
Title: |
Chief Executive Officer |
EXERCISE NOTICE
BRILLIA INC.
WARRANT DATED NOVEMBER 29, 2024
The undersigned Holder hereby irrevocably elects
to purchase _____________ Class A Ordinary Shares pursuant to the above referenced Warrant. Capitalized terms used herein and not otherwise
defined have the respective meanings set forth in the Warrant.
(1) The undersigned Holder
hereby exercises its right to purchase _________________ Warrant Shares pursuant to the Warrant.
(2) The holder shall pay the
sum of $____________ to the Company in accordance with the terms of the Warrant.
(3) Pursuant to this Exercise
Notice, the Company shall deliver to the holder _______________ Warrant Shares in accordance with the terms of the Warrant.
(4) By its delivery of this
Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder
will not beneficially own in excess of the number of Class A Ordinary Shares (determined in accordance with Section 13(d) of the Securities
Exchange Act of 1934) permitted to be owned under Section 11 of this Warrant to which this notice relates.
| Dated: ___________, 202_ |
Name of Holder: |
| |
|
| |
(Print) |
|
| |
|
|
| |
By: |
|
| |
Name: |
|
| |
Title: |
|
(Signature must conform in all respects to name of holder as specified
on the face of the Warrant)
Warrant
Shares Exercise Log
| Date | |
Number of Warrant
Shares Available to
be Exercised | | |
Number of Warrant
Shares Exercised | | |
Number of Warrant
Shares Remaining to
be Exercised | |
| | |
| | | |
| | | |
| | |
ASSIGNMENT
FORM
(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)
[To be completed and signed
only upon transfer of Warrant]
FOR VALUE RECEIVED, the undersigned
hereby sells, assigns and transfers unto ________________________________ the right represented by the above-captioned Warrant to purchase
____________ Class A Ordinary Shares to which such Warrant relates and appoints ________________ attorney to transfer said right on the
books of the Company with full power of substitution in the premises.
| Dated:
______________, 202_ |
|
|
| |
|
(Signature must conform in all respects to name of holder as specified on the face of the Warrant) |
| |
|
|
| |
|
Address of Transferee |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| In
the presence of: |
|
|
| |
|
|
| |
|
|
Exhibit 10.1
Lock-Up Agreement
November 26, 2024
A.G.P./Alliance Global Partners
590 Madison Avenue, 28th Floor
New York, NY 10022
Ladies and Gentlemen:
The undersigned understands
that A.G.P./Alliance Global Partners, as Representative of the several underwriters (the “Representative”), proposes
to enter into an Underwriting Agreement (the “Underwriting Agreement”) with BrilliA Inc, a corporation formed under
the laws of Cayman Islands (the “Company”), providing for the public offering (the “Public Offering”)
by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the “Underwriters”) of Class A ordinary
shares, par value $0.00005 per share, of the Company (the “Class A Shares”). Capitalized terms used herein and not
otherwise defined shall have the meanings set forth in the Underwriting Agreement.
To induce the Representative
to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent
of the Representative, the undersigned will not, during the period commencing on the date hereof and ending six months after the date
of the Underwriting Agreement relating to the Public Offering (the “Lock-Up Period”), (1) offer, pledge, sell, contract
to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Class A Shares or any securities convertible into
or exercisable or exchangeable for Class A Shares, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”); (2) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the
Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities,
in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly
disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement
relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up
Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up Securities
acquired in open market transactions after the completion of the Public Offering; provided that no filing under Section 16(a) of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shall be voluntarily made in connection with
subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up Securities as a bona fide
gift, by will or intestacy or to a family member or trust for the benefit of a family member (for purposes of this lock-up agreement,
“family member” means any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of
Lock-Up Securities to a charity or educational institution; or (d) if the undersigned, directly or indirectly, controls a corporation,
partnership, limited liability company or other business entity, any transfers of Lock-Up Securities to any shareholder, partner or member
of, or owner of similar equity interests in, the undersigned, as the case may be; provided that in the case of any transfer pursuant to
the foregoing clauses (b), (c) or (d), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall
sign and deliver to the Representative a lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing under
Section 16(a) of the Exchange Act shall be voluntarily made. The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company’s transfer agent and registrar against the transfer of the undersigned’s Lock-Up Securities except in compliance
with this lock-up agreement.
If the undersigned is an officer
or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any issuer-directed
or “friends and family” Class A Shares, if any, that the undersigned may purchase in the Public Offering; and (ii) the Representative
agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection
with a transfer of Lock-Up Securities, the Representative will notify the Company of the impending release or waiver. The provisions of
this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration
and (b) the transferee has agreed in writing to be bound by the same terms described in this lock-up agreement to the extent and for the
duration that such terms remain in effect at the time of such transfer.
No provision in this agreement
shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable or exchangeable
for or convertible into Shares, as applicable; provided that the undersigned does not transfer the Class A Shares acquired on such
exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to the terms of this lock-up agreement.
In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification of a so-called “10b5-1”
plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the sale of any Lock-Up Securities
within the Lock-Up Period).
The undersigned understands
that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering.
The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned’s heirs,
legal representatives, successors and assigns.
The undersigned understands
that, if the Underwriting Agreement is not executed by December 5, 2024 or if the Underwriting Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to the initial closing date of the Class A Shares to be sold thereunder,
then this lock-up agreement shall be void and of no further force or effect.
[Remainder of Page Intentionally Blank]
Exhibit
99.1
BrilliA
Inc Announces Pricing of Initial Public Offering
SINGAPORE, November 26, 2024 – BrilliA
Inc (“BRIA” or “the Company”) today announced the pricing of its initial public offering of an aggregate
of 2,500,000 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by BRIA at a public
offering price of $4.00 per share.
In addition, the Company has granted the underwriters
a 45-day option to purchase up to an additional 375,000 shares of its Class A Ordinary Shares at the initial public offering price (“the
Overallotment”), less underwriting discounts and commissions. The gross proceeds to BRIA from the Offering (assuming that
the Overallotment is not exercised), before deducting underwriting discounts and commissions and estimated offering expenses payable by
BRIA, is expected to be approximately $10,000,000.
The shares are expected to begin trading on the
NYSE American under the ticker symbol “BRIA” on November 27, 2024. The Offering is expected to close on November 29, 2024,
subject to customary closing conditions.
The offering is conducted on a firm commitment
basis. A.G.P./Alliance Global Partners (“A.G.P.”) is the sole Book-Running manager for the offering. Mourant Ozannes
LLP is acting as Cayman Islands and British Virgin Islands legal counsel and Ortoli Rosenstadt LLP is acting as U.S. legal counsel, respectively,
to the Company, and Lewis Brisbois Bisgaard & Smith LLP is acting as U.S. legal counsel to A.G.P. for the Offering.
The Offering is being conducted pursuant to
the Company’s Registration Statement on Form F-1 (File No. 333-282056) previously filed with and subsequently declared effective
by the U.S. Securities and Exchange Commission (“SEC”) on November, 19 2024. The Offering is being made only by means
of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC
for more information about the Company and the Offering. You may get these documents for free by visiting EDGAR on the SEC’s Website
at www.sec.gov. Alternatively, electronic copies of the prospectus relating to the Offering may be obtained from A.G.P./Alliance Global
Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, by phone at +1 (212) 624-2060, or by email at prospecuts@allianceg.com.
This press release has been prepared for informational
purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities
may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this press release are “forward-looking
statements” as defined under the federal securities laws, including, but not limited to, the Company’s expectations regarding
the completion, timing and size of the proposed Offering and statements regarding the use of proceeds from the sale of the Company’s
shares in the Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s
current expectations and projections about future events that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find
many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”,
“should”, “seek”, “estimate”, “will”, “aim” and “anticipate”,
or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking
statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you
that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration
statement and other filings with the SEC.
About BrilliA Inc
BrilliA has evolved from an Original Design Manufacturer
into a comprehensive one-stop service cross-border solution provider for ladies' intimate apparel brands, managing sales and customer
relationships with major clients like Fruit of the Loom, Hanes Brands Inc and H&M, with the expertise in handling sourcing, design,
prototyping, supply chain to logistic management as well as quality control of products manufactured by independent third party manufacturing
facilities for their customers worldwide.
For further information, please contact:
BrilliA Inc Contact:
220 Orchard Road, Unit 05-01, Midpoint Orchard
Singapore 238852
(+65) 6235 3388
Email: info@brilliaincorporated.com
Underwriter Inquiries:
A.G.P./Alliance Global Partners
590 Madison Avenue, 28th Floor
New York, NY 10022
Email: prospectus@allianceg.com
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
Exhibit
99.2
BrilliA
Inc Announces Closing of Initial Public Offering
SINGAPORE,
November 29, 2024 – BrilliA Inc (“BRIA” or “the Company”) today announced the closing of
its previously announced initial public offering of an aggregate of 2,500,000 Class A Ordinary Shares (the “Offering ”)
at an offering price of $4.00 per share to the public, for a total of $10,000,000 in gross proceeds to the Company, before deducting
underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American stock exchange on November 27,
2024, under the ticker symbol "BRIA."
In
addition, the Company has granted the underwriters an option, exercisable within 45 days from the closing date of the Offering, to purchase
up to an additional 375,000 Class A Ordinary Shares at the Offering Price, representing
15% of the Class A Ordinary
Shares sold in the Offering.
The
net proceeds from the initial public offering are expected to be used for development of the digital marketing platform, research and
development, expansion of existing B2B business, and general working capital and corporate purposes.
The
offering was conducted on a firm commitment basis. A.G.P./Alliance Global Partners (“A.G.P.”) was the sole Book-Running
manager for the offering. Mourant Ozannes LLP acted as Cayman Islands and British Virgin Islands legal counsel and Ortoli Rosenstadt
LLP acted as U.S. legal counsel, respectively, to the Company, and Lewis Brisbois Bisgaard & Smith LLP acted as U.S. legal counsel
to A.G.P. for the Offering.
The
Offering was conducted pursuant to the Company’s Registration Statement on Form F-1 (File No. 333-282056) previously filed with
and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on November 19, 2024. The
Offering was made only by means of a prospectus, forming a part of the registration statement. Electronic copies of the final prospectus
relating to the Offering may be obtained for free by visiting EDGAR on the SEC’s Website at www.sec.gov. Alternatively, copies
of the prospectus relating to the Offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue,
28th Floor, New York, NY 10022, by phone at +1 (212) 624-2060, or by email at prospecuts@allianceg.com.
This
press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer
to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain
statements in this press release are “forward-looking statements” as defined under the federal securities laws, including,
but not limited to, the Company’s expectations regarding the completion, timing and size of the proposed Offering and statements
regarding the use of proceeds from the sale of the Company’s shares in the Offering. These forward-looking statements involve known
and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that
the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the
expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of
words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”,
“estimate”, “will”, “aim” and “anticipate”, or other similar expressions in this press
release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations
expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct,
and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.
About
BrilliA Inc
BrilliA
has evolved from an Original Design Manufacturer into a comprehensive one-stop service cross-border solution provider for ladies' intimate
apparel brands, managing sales and customer relationships with major clients like Fruit of the Loom, Hanes Brands Inc and H&M, with
the expertise in handling sourcing, design, prototyping, supply chain to logistic management as well as quality control of products manufactured
by independent third party manufacturing facilities for their customers worldwide.
For
further information, please contact:
BrilliA
Inc Contact:
220
Orchard Road, Unit 05-01, Midpoint Orchard
Singapore
238852
(+65)
6235 3388
Email:
info@brilliaincorporated.com
Underwriter
Inquiries:
A.G.P./Alliance
Global Partners
590
Madison Avenue, 28th Floor
New
York, NY 10022
Email:
prospectus@allianceg.com
Investor
Relations Inquiries:
Skyline
Corporate Communications Group, LLC
Scott
Powell, President
1177
Avenue of the Americas, 5th Floor
New
York, New York 10036
Office:
(646) 893-5835
Email:
info@skylineccg.com
BrilliA (AMEX:BRIA)
Historical Stock Chart
From Nov 2024 to Dec 2024
BrilliA (AMEX:BRIA)
Historical Stock Chart
From Dec 2023 to Dec 2024
